drugset / Trial / NCT01428362
VI-1121 for the Treatment Alzheimer's Disease
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether VI-1121 is safe, well tolerated, and effective as a daily treatment for Alzheimer's disease that is worsening despite current treatment.
Timeline
- Start
- 2011-08
- Primary completion
- 2013-08
- Completion
- 2013-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VI-1121 | Unknown | — | — |